{"altmetric_id":22036716,"counts":{"readers":{"mendeley":11,"citeulike":0,"connotea":0},"total":{"posts_count":21},"news":{"unique_users_count":9,"unique_users":["medicalxpress","entornio_inteligente","abc_es","la_voz_digital","voice_of_america","eurekalert","health_canal","the_body","drug_discovery_and_development"],"posts_count":9},"twitter":{"unique_users_count":9,"unique_users":["TAGHIVscience","iu22ie33","jclinicalinvest","japineda_","cpvfarvalme","hjillianh","patrickreville","infdisease_news","ZapotlanVIHVO"],"posts_count":10},"facebook":{"unique_users_count":2,"unique_users":["165951396774740","589704904403630"],"posts_count":2}},"selected_quotes":["More data supporting vorinostat can effectively reverse #HIV latency","Interesting use of HDAC inhibitors to reverse HIV latency. Could see similar uses to induce cancer neoantigens, i.e.","The HDAC inhibitor vorinostat safely and effectively reverses HIV latency @UNC_SOM @UNC_Health\u2026","The HDAC inhibitor vorinostat safely and effectively reverses HIV latency @UNC_SOM @UNC_Health_Care #HIV #AIDS"],"citation":{"abstract":"The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of latent infection. We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency.\nIn a study of 16 HIV-infected, aviremic individuals, we measured resting CD4+ T cell-associated HIV RNA ex vivo and in vivo following a single exposure to VOR, and then in vivo after a pair of doses separated by 48 or 72 hours, and finally following a series of 10 doses given at 72-hour intervals.\nSerial VOR exposures separated by 72 hours most often resulted in an increase in cell-associated HIV RNA within circulating resting CD4+ T cells. VOR was well tolerated by all participants. However, despite serial reversal of latency over 1 month of VOR dosing, we did not observe a measurable decrease (>0.3 log10) in the frequency of latent infection within resting CD4+ T cells.\nThese findings outline parameters for the experimental use of VOR to clear latent infection. Latency reversal can be achieved by VOR safely and repeatedly, but effective depletion of persistent HIV infection will require additional advances. In addition to improvements in latency reversal, these advances may include the sustained induction of potent antiviral immune responses capable of recognizing and clearing the rare cells in which HIV latency has been reversed.\nClinicaltrials.gov NCT01319383.\nNIH grants U01 AI095052, AI50410, and P30 CA016086 and National Center for Advancing Translational Sciences grant KL2 TR001109.","altmetric_jid":"4f6fa4f03cf058f610002cff","authors":["Nancie M. Archin","Jennifer L. Kirchherr","Julia A.M. Sung","Genevieve Clutton","Katherine Sholtis","Yinyan Xu","Brigitte Allard","Erin Stuelke","Angela D. Kashuba","Joann D. Kuruc","Joseph Eron","Cynthia L. Gay","Nilu Goonetilleke","David M. Margolis"],"doi":"10.1172\/jci92684","first_seen_on":"2017-07-17T22:59:18+00:00","funders":["niehs","niaid","nci"],"handles":[],"issns":["0021-9738","1558-8238"],"journal":"Journal of Clinical Investigation","last_mentioned_on":1501873200,"links":["https:\/\/www.jci.org\/articles\/view\/92684","https:\/\/www.jci.org\/articles\/view\/92684?utm_content=buffere0ced&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer","https:\/\/www.jci.org\/articles\/view\/92684?utm_content=bufferb042e&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer","http:\/\/dx.doi.org\/10.1172\/JCI92684"],"pdf_url":"http:\/\/www.jci.org\/articles\/view\/92684\/files\/pdf","pmid":"28714868","pubdate":"2017-07-17T00:00:00+00:00","publisher":"American Society for Clinical Investigation","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["medicine"],"title":"Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/interval-dosing-hdac-inhibitor-vorinostat-effectively-reverses-hiv-latency"},"altmetric_score":{"score":77,"score_history":{"1y":77,"6m":77,"3m":77,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":77},"context_for_score":{"all":{"total_number_of_other_articles":8346622,"mean":7.0389291726478,"rank":116880,"this_scored_higher_than_pct":98,"this_scored_higher_than":8229846,"rank_type":"exact","sample_size":8346622,"percentile":98},"similar_age_3m":{"total_number_of_other_articles":201248,"mean":13.108852882279,"rank":7077,"this_scored_higher_than_pct":96,"this_scored_higher_than":194157,"rank_type":"exact","sample_size":201248,"percentile":96},"this_journal":{"total_number_of_other_articles":6557,"mean":13.790405735204,"rank":195,"this_scored_higher_than_pct":97,"this_scored_higher_than":6361,"rank_type":"exact","sample_size":6557,"percentile":97},"similar_age_this_journal_3m":{"total_number_of_other_articles":95,"mean":37.411382978723,"rank":16,"this_scored_higher_than_pct":83,"this_scored_higher_than":79,"rank_type":"exact","sample_size":95,"percentile":83}}},"demographics":{"poster_types":{"member_of_the_public":5,"researcher":2,"practitioner":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":5,"Practitioners (doctors, other healthcare professionals)":1,"Science communicators (journalists, bloggers, editors)":1,"Scientists":2}},"mendeley":{"by_status":{"Researcher":4,"Student  > Ph. D. Student":4,"Student  > Master":2,"Other":1},"by_discipline":{"Engineering":1,"Medicine and Dentistry":4,"Immunology and Microbiology":2,"Agricultural and Biological Sciences":2,"Biochemistry, Genetics and Molecular Biology":1,"Mathematics":1}}},"geo":{"twitter":{"US":5,"ES":2,"MX":1}}},"posts":{"news":[{"title":"Study advances the ability to expose latent HIV","url":"http:\/\/ct.moreover.com\/?a=31237116241&p=1pl&v=1&x=ox7uHHx-vn5eVsNOAlZShg","license":"public","citation_ids":[22036716],"posted_on":"2017-07-17T20:16:25+00:00","summary":"David Margolis, M.D. Credit: David Kinton, UNC School of Medicine Exposing hidden HIV reservoirs so that they can be cleared is a strategy being tested in efforts to develop therapies to cure the nearly 40 million people worldwide living with HIV.","author":{"name":"MedicalXpress","url":"http:\/\/medicalxpress.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/152\/normal\/image.png?1369925783"}},{"title":"VENEZUELA: \u2032Un f\u00e1rmaco descubre el escondite del VIH\u2032","url":"http:\/\/ct.moreover.com\/?a=31249556043&p=1pl&v=1&x=FNksoWri9CK53zMZbsdldA","license":"public","citation_ids":[22036716],"posted_on":"2017-07-18T00:00:00+00:00","summary":"\/ Un estudio muestra como un f\u00e1rmaco denominado vorinostat no es solo seguro para su uso en humanos con la infecci\u00f3n, sino que es muy eficaz a la hora de revertir la fase de latencia del VIH, facilitando as\u00ed su destrucci\u00f3n.","author":{"name":"Entornio Inteligente","url":"http:\/\/www.entornointeligente.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/897\/normal\/Screen_Shot_2016-01-13_at_16.16.47.png?1452701825"}},{"title":"Un f\u00e1rmaco es capaz de sacar al VIH de sus reservorios para su destrucci\u00f3n","url":"http:\/\/ct.moreover.com\/?a=31237169500&p=1pl&v=1&x=1_utncJgpmxjxXRruOTbbw","license":"public","citation_ids":[22036716],"posted_on":"2017-07-17T20:23:34+00:00","summary":"Si bien a d\u00eda de hoy existen terapias antirretrovirales muy eficaces para controlar la infecci\u00f3n por el virus de la inmunodeficiencia humana (VIH), todav\u00eda no se ha encontrado un tratamiento capaz de curarla.","author":{"name":"ABC.es","url":"http:\/\/www.abc.es\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/362\/normal\/Screen_Shot_2016-01-12_at_14.08.36.png?1452607731"}},{"title":"Un f\u00e1rmaco es capaz de sacar al VIH de sus reservorios para su destrucci\u00f3n","url":"http:\/\/ct.moreover.com\/?a=31237172638&p=1pl&v=1&x=KnTmm3Djvt6MiKrwUOEa7Q","license":"public","citation_ids":[22036716],"posted_on":"2017-07-17T20:23:56+00:00","summary":"El \u2018vorinostat\u2019 revierte de forma segura la fase de latencia del VIH e identifica las c\u00e9lulas en las que se esconde el virus para facilitar su eliminaci\u00f3n Si bien a d\u00eda de hoy existen terapias antirretrovirales muy eficaces para controlar la infecci\u00f3n\u2026","author":{"name":"La Voz Digital","url":"http:\/\/www.lavozdigital.es","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/825\/normal\/Screen_Shot_2016-01-27_at_10.40.51.png?1453891340"}},{"title":"Research Tries 'Shock and Kill' to Eliminate HIV","url":"http:\/\/ct.moreover.com\/?a=31238233240&p=1pl&v=1&x=weQQD1H5p1fe53iywP6IGA","license":"public","citation_ids":[22036716,22036716],"posted_on":"2017-07-17T22:45:22+00:00","summary":"WASHINGTON \u2014 Researchers working on a one-two punch to eliminate HIV say their first punch has landed and they can start working on the second, though plenty of work will be needed on both fronts before a cure is available.","author":{"name":"Voice of America","url":"http:\/\/www.voanews.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/111\/normal\/image.png?1369926568"}},{"title":"UNC study advances the ability to expose latent HIV","url":"http:\/\/ct.moreover.com\/?a=31239174260&p=1pl&v=1&x=G8QqjiaK7I8nLT3piR8zQQ","license":"public","citation_ids":[22036716],"posted_on":"2017-07-17T04:00:00+00:00","summary":"Chapel Hill, NC - Exposing hidden HIV reservoirs so that they can be cleared is a strategy being tested in efforts to develop therapies to cure the nearly 40 million people worldwide living with HIV.","author":{"name":"EurekAlert!","url":"http:\/\/www.eurekalert.org\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/077\/normal\/image.png?1369859505"}},{"title":"UNC Study Advances the Ability to Expose Latent HIV - Healthcanal.com","url":"http:\/\/ct.moreover.com\/?a=31276100953&p=1pl&v=1&x=IE-xCJVkWurvobGry5rKpQ","license":"public","citation_ids":[22036716],"posted_on":"2017-07-21T07:32:49+00:00","summary":"Chapel Hill, NC \u2013 Exposing hidden HIV reservoirs so that they can be cleared is a strategy being tested in efforts to develop therapies to cure the nearly 40 million people worldwide living with HIV.","author":{"name":"Health Canal","url":"http:\/\/www.healthcanal.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/221\/normal\/image.png?1370446573"}},{"title":"Scientists Hone in on the Best Way to Expose HIV Hidden in the Viral Reservoir, a Crucial Step Toward an Eventual Cure","url":"http:\/\/ct.moreover.com\/?a=31319635169&p=1pl&v=1&x=iXTQz4gIn3ylQ5UrldcSuw","license":"public","citation_ids":[22036716],"posted_on":"2017-07-25T22:54:01+00:00","summary":"Researchers at the University of North Carolina are one step closer in the quest to find a cure for HIV, announcing earlier this month that they have identified a better dosing strategy for a drug that exposes HIV hiding inside the body's viral\u2026","author":{"name":"The Body","url":"http:\/\/www.thebody.com\/index.html?ic=3002","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/002\/532\/normal\/Screen_Shot_2016-10-26_at_09.58.02.png?1477472339"}},{"title":"Study Advances Ability to Expose Latent HIV","url":"http:\/\/ct.moreover.com\/?a=31422030101&p=1pl&v=1&x=Ut5zthzASCrsIdBpOzNIsg","license":"public","citation_ids":[22036716],"posted_on":"2017-08-04T19:00:00+00:00","summary":"Exposing hidden HIV reservoirs so that they can be cleared is a strategy being tested in efforts to develop therapies to cure the nearly 40 million people worldwide living with HIV.","author":{"name":"Drug Discovery and Development ","url":"http:\/\/www.dddmag.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/228\/normal\/Screen_Shot_2014-10-17_at_15.44.03.png?1413557084"}}],"twitter":[{"url":"http:\/\/twitter.com\/TAGHIVscience\/statuses\/887291288978169858","license":"gnip","citation_ids":[22036716],"posted_on":"2017-07-18T12:41:43+00:00","author":{"name":"TAGHIVscience","url":"http:\/\/www.treatmentactiongroup.org\/basic-science","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000408365735\/6faf498418bf2dc907cbb5eb08461603_normal.png","description":"Twitter for TAG's Basic Science, Vaccines & Cure Project, by Richard Jefferys. Primary Treatment Action Group twitter is @TAGTeam_Tweets","id_on_source":"TAGHIVscience","tweeter_id":"64767085","geo":{"lt":40.71427,"ln":-74.00597,"country":"US"},"followers":2002},"tweet_id":"887291288978169858"},{"url":"http:\/\/twitter.com\/iu22ie33\/statuses\/887362359056052224","license":"gnip","rt":["TAGHIVscience"],"citation_ids":[22036716],"posted_on":"2017-07-18T17:24:07+00:00","author":{"name":"Bill Wang","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000559502126\/0ad7c1d95b7c341d9ae58a28ba3dd295_normal.jpeg","description":"HIV-1 investigator at National Institutes of Health. Own medical degree and PhD. More than 10 years HIV research experiences, focuses on HIV-immunology studies.","id_on_source":"iu22ie33","tweeter_id":"373113388","geo":{"lt":38.91706,"ln":-77.00025,"country":"US"},"followers":84},"tweet_id":"887362359056052224"},{"url":"http:\/\/twitter.com\/jclinicalinvest\/statuses\/887678444909277184","license":"gnip","citation_ids":[22036716],"posted_on":"2017-07-19T14:20:08+00:00","author":{"name":"J. Clin. Invest.","url":"http:\/\/www.jci.org","image":"https:\/\/pbs.twimg.com\/profile_images\/448859171014725632\/tbpzy0t3_normal.png","description":"The Journal of Clinical Investigation is a premiere venue for discoveries in basic and clinical biomedical science that will advance the practice of medicine.","id_on_source":"jclinicalinvest","tweeter_id":"223605846","geo":{"lt":42.27756,"ln":-83.74088,"country":"US"},"followers":4843},"tweet_id":"887678444909277184"},{"url":"http:\/\/twitter.com\/japineda_\/statuses\/887705646157746176","license":"gnip","citation_ids":[22036716],"posted_on":"2017-07-19T16:08:13+00:00","author":{"name":"Juan A. Pineda","image":"https:\/\/pbs.twimg.com\/profile_images\/681753976186994688\/IHl58KXF_normal.jpg","description":"M\u00e9dico. Enfermedades Infecciosas. Investigador.","id_on_source":"japineda_","tweeter_id":"324559268","geo":{"lt":37.38241,"ln":-5.97613,"country":"ES"},"followers":145},"tweet_id":"887705646157746176"},{"url":"http:\/\/twitter.com\/cpvfarvalme\/statuses\/887756176645120002","license":"gnip","rt":["japineda_"],"citation_ids":[22036716],"posted_on":"2017-07-19T19:29:00+00:00","author":{"name":"AF en VIH, VHC y VHB","url":"http:\/\/farmaciavalmecpv.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3374760685\/7bf630000ca0d4e699b3b1590b6efa06_normal.png","description":"Since 2009 helping to obtain the pharmacoterapeutic aims of our HIV, HCV or HBV patients and re-defining the Pharmaceutical Care. We believe in CMO model.","id_on_source":"cpvfarvalme","tweeter_id":"428978877","geo":{"lt":40,"ln":-4,"country":"ES"},"followers":1220},"tweet_id":"887756176645120002"},{"url":"http:\/\/twitter.com\/hjillianh\/statuses\/887786465836625923","license":"gnip","rt":["jclinicalinvest"],"citation_ids":[22036716],"posted_on":"2017-07-19T21:29:22+00:00","author":{"name":"Jillian Hurst","image":"https:\/\/pbs.twimg.com\/profile_images\/877260157033566208\/8y1_yxNG_normal.jpg","description":"Pediatric research program manager, former scientist and JCI science editor, beekeeper, food snob, Durhamite. Opinions do not represent those of my employer.","id_on_source":"hjillianh","tweeter_id":"91408284","geo":{"lt":35.99403,"ln":-78.89862,"country":"US"},"followers":360},"tweet_id":"887786465836625923"},{"url":"http:\/\/twitter.com\/patrickreville\/statuses\/887814029015740417","license":"gnip","citation_ids":[22036716,22206787],"posted_on":"2017-07-19T23:18:53+00:00","author":{"name":"Patrick Reville, MD","url":"https:\/\/scholar.google.com\/citations?user=onD3Vd8AAAAJ&hl=en","image":"https:\/\/pbs.twimg.com\/profile_images\/835890010209533952\/wGeUG6AK_normal.jpg","description":"Physician-Scientist in training | Interested in Cancer #Immunotherapy and #Immunogenetics | No COIs, tweets \u2260 med advise or represent any institutional views","id_on_source":"patrickreville","tweeter_id":"244297905","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":81},"tweet_id":"887814029015740417"},{"url":"http:\/\/twitter.com\/infdisease_news\/statuses\/888808399806377989","license":"gnip","citation_ids":[22036716],"posted_on":"2017-07-22T17:10:10+00:00","author":{"name":"Infectious Disease","url":"http:\/\/www.immunologyofinfectiousdiseasenews.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/748298535754293248\/VMW9hG24_normal.jpg","description":"The online resource for the infectious disease community. Check out our sister publications, @Immune_News and @HumanImmuneNews. \nFB: http:\/\/ow.ly\/VGAaq","id_on_source":"infdisease_news","tweeter_id":"887203562","geo":{"lt":null,"ln":null},"followers":4438},"tweet_id":"888808399806377989"},{"url":"http:\/\/twitter.com\/ZapotlanVIHVO\/statuses\/891233086209277952","license":"gnip","citation_ids":[22036716],"posted_on":"2017-07-29T09:45:00+00:00","author":{"name":"Zapotl\u00e1n VIHVO A. C.","url":"http:\/\/www.zapotlanvihvo.org","image":"https:\/\/pbs.twimg.com\/profile_images\/907374776749920256\/qaugCRva_normal.jpg","description":"Trabajamos por la salud sexual integral y la defensa de los derechos sexuales, haciendo \u00e9nfasis en la prevenci\u00f3n y detecci\u00f3n oportuna del VIH.","id_on_source":"ZapotlanVIHVO","tweeter_id":"606945273","geo":{"lt":19.70466,"ln":-103.4617,"country":"MX"},"followers":1528},"tweet_id":"891233086209277952"},{"url":"http:\/\/twitter.com\/ZapotlanVIHVO\/statuses\/891587923719536641","license":"gnip","citation_ids":[22036716],"posted_on":"2017-07-30T09:15:00+00:00","author":{"name":"Zapotl\u00e1n VIHVO A. C.","url":"http:\/\/www.zapotlanvihvo.org","image":"https:\/\/pbs.twimg.com\/profile_images\/907374776749920256\/qaugCRva_normal.jpg","description":"Trabajamos por la salud sexual integral y la defensa de los derechos sexuales, haciendo \u00e9nfasis en la prevenci\u00f3n y detecci\u00f3n oportuna del VIH.","id_on_source":"ZapotlanVIHVO","tweeter_id":"606945273","geo":{"lt":19.70466,"ln":-103.4617,"country":"MX"},"followers":1528},"tweet_id":"891587923719536641"}],"facebook":[{"title":"JCI -\nInterval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1467495036620363&id=165951396774740","license":"public","citation_ids":[22036716],"posted_on":"2017-07-19T13:40:02+00:00","summary":"The HDAC inhibitor vorinostat safely and effectively reverses HIV latency\n\nA latent HIV reservoir can persist in resting CD4+ T cells for years after antiretroviral therapy clears immune cells with active infection. Recently, latency-reversing agents have","author":{"name":"Journal of Clinical Investigation","url":"https:\/\/www.facebook.com\/165951396774740","facebook_wall_name":"Journal of Clinical Investigation","image":"https:\/\/graph.facebook.com\/165951396774740\/picture","id_on_source":"165951396774740"}},{"title":"Journal of Clinical Investigation","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1747369005303875&id=589704904403630","license":"public","citation_ids":[22036716],"posted_on":"2017-07-19T16:21:01+00:00","summary":"The HDAC inhibitor vorinostat safely and effectively reverses HIV latency\n\nA latent HIV reservoir can persist in resting CD4+ T cells for years after antiretroviral therapy clears immune cells with active infection. Recently, latency-reversing agents have","author":{"name":"SJAbioscience","url":"https:\/\/www.facebook.com\/589704904403630","facebook_wall_name":"SJAbioscience","image":"https:\/\/graph.facebook.com\/589704904403630\/picture","id_on_source":"589704904403630"}}]}}